Xiaomeng Dai

Zhejiang Chinese Medical University — China

Medicine · Health Sciences

29h-index2.7kcitations94works12.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(21), Cancer Genomics and Diagnostics(19), RNA modifications and cancer(19), Cancer Immunotherapy and Biomarkers(16), Immune cells in cancer(12)

Publications94 total

A KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis
International Journal of Biological Macromolecules·2025Open Access
Depletion of <i>Sorcs3</i> Activates Totipotency in Mouse Embryonic Stem Cells by Modulating Key Signaling Pathways
Advanced Science·2025Open Access
364 Systems immunology-guided <i>in vivo</i> CRISPR screens reveal a multifunctional E3 ligase that enhances adoptive T cell therapy for solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study
Cancer Immunology Immunotherapy·2025· 5 citedOpen Access
Lactylation in cancer: Advances and opportunities for treatment resistance
Clinical and Translational Medicine·2025· 3 citedOpen Access
Injectable HMME‐Loading Emulsion Hydrogel for Ultrasound‐Triggered Release and Enhanced Sonodynamic Immunotherapy
Advanced Healthcare Materials·2025· 1 cited
Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns
Lung Cancer·2025· 1 cited
Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
Cell Discovery·2025· 6 citedOpen Access
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure
Hepatology·2025· 3 cited
Amplifying Anti‐Tumor Immune Responses via Mitochondria‐Targeting Near‐Infrared Photodynamic Therapy
Advanced Science·2025· 4 citedOpen Access
Targeting inflammasomes as an immunotherapeutic strategy for cancer
Journal of Translational Medicine·2025· 11 citedOpen Access
Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer
Molecular Therapy·2025· 9 citedOpen Access
Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis
Oncogene·2025· 8 cited
Injectable celastrol-loading emulsion hydrogel for immunotherapy of low-immunogenic cancer
Journal of Nanobiotechnology·2025· 5 citedOpen Access
Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma
Hepatology·2025· 14 cited
In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma
Gastroenterology report·2025Open Access
“Convex Lens” of DNA damage: A nanomedicine enhances anti-PD-1 immunotherapy as immunogenic cell death inducer for “cold” melanoma
Nano Today·2024· 2 cited
Dexmedetomidine therapy promotes cardiac dysfunction and increases mortality in sepsis: A translational study
International Immunopharmacology·2024· 3 citedOpen Access
In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies
Nano Today·2024· 2 cited
A Pathologically Friendly Strategy for Determining the Organ‐specific Spatial Tumor Microenvironment Topology in Lung Adenocarcinoma Through the Integration of snRandom‐seq and Imaging Mass Cytometry
Advanced Science·2024· 9 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Weijia Fang(18), Xuanwen Bao(18), Peng Zhao(13), Lulu Liu(11), Hangyu Zhang(11), Yi Zheng(11), Yuzhi Jin(10), Xudong Zhu(9), Chao Wan(8), Honglin Jin(8), Qihan Fu(8), Weihong Tian(8), Kunyu Yang(7), Yajie Sun(6), Jonathan F. Lovell(6), Zhou Tong(6), Shengli Yang(6), Xin Shan(6), Jinlin Cheng(6), Xiangxu Tang(6)